Janssen’s results for subcutaneous formulation of DARZALEX ®▼ (Daratumumab) combination
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced results from the first randomised Phase 3 study investigating the subcutaneous formulation of DARZALEX®▼...
Kite receives EMA approval for CART-T cell therapy manufacturing facility
Kite receives European Medicines Agency (EMA) approval for CART-T cell therapy manufacturing facility in Europe. Kite, a Gilead Company has received approval to implement a...
NICE approves new rare lung cancer treatment from Roche
The National Institute for Health and Care Excellence (NICE) has approved a new rare lung cancer treatment. NICE has published its decision to grant a...
Janssen’s COVID-19 vaccine trial to commence in July
Janssen's COVID-19 vaccine trial is to commence in the second half of July, earlier than expected. Johnson & Johnson has announced that through its...
AstraZeneca to showcase new data on type-2 diabetes and cardiorenal complications
AstraZeneca is to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020. It will present new data from the landmark Phase III...
Advancing digital technology in life sciences R&D and healthcare
The Pistoia Alliance launches new project to advance digital technology in life sciences R&D and healthcare to realise the value of digital health. The first...
New study trials use of CT-P13 to accelerate COVID-19 recovery
Celltrion Healthcare is partnering with the University of Oxford and University Hospitals Birmingham to study the use of CT-P13 (biosimilar infliximab) to accelerate COVID-19...
Lilly announces start of a Phase 1 study for its second potential COVID-19 antibody...
Eli Lilly and Company announced that its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralising COVID-19...
New data on subcutaneous formulation of infliximab
At the European E-Congress of Rheumatology 2020 (The European League Against Rheumatism (EULAR) 2020 E-Congress), Celltrion Healthcare showcased three sets of data relating to...
First adjuvanted quadrivalent influenza vaccine receives EU approval
The European Commission has given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the...
Latest articles
NICE recommends ADCETRIS▼ (brentuximab vedotin), in combination with chemotherapy, as frontline treatment for a...
Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended ADCETRIS (brentuximab vedotin) with cyclophosphamide, doxorubicin and prednisone...
CMA formally concludes fludrocortisone investigation
The Competition and Markets Authority (CMA) has formally concluded its fludrocortison investigation and found that three pharmaceutical companies took part in an illegal arrangement...
MHRA response to Independent Medicines and Medical Devices Safety Review
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its response to the Independent Medicines and Medical Devices Safety Review. In its response, the...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
The ABPI Code & Virtual Promotional Meetings
As the pharma industry looks to virtual meetings and teams work remotely, what considerations are there around the ABPI Code and virtual promotional meetings? Whilst...
First Do No Harm: Independent Medicines and Medical Devices Safety Review publishes its recommendations
The Independent Medicines and Medical Devices Safety Review, chaired by Baroness Julia Cumberlege, has today published its report. Titled 'First Do No Harm', it comes...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
NICE recommends ADCETRIS▼ (brentuximab vedotin), in combination with chemotherapy, as frontline treatment for a...
Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended ADCETRIS (brentuximab vedotin) with cyclophosphamide, doxorubicin and prednisone...